title: Short-term oral treatment of canine benign prostatic hypertrophy with chlormadinone acetate.
abstract: Ten beagle dogs (4-8 years of age) with benign prostatic hypertrophy were treated daily for 7 or 14 days by a daily oral administration of chlormadinone acetate (CMA), an anti-androgenic preparation, at a dose of 0.5 or 2.0 mg/kg/day. The groups of dogs treated with CMA at a dose of 2.0 mg/kg showed a greater reduction of the prostatic volume during 7 or 14 days of treatment than the group treated with 0.5 mg/kg of CMA. At 56 and 84 days after the start of CMA treatment, prostate volume was reduced to 63 and 79% of the pre-administration volume, respectively. No marked decrease in plasma LH or testosterone was found after the CMA treatment. These results indicate that the therapeutic effects of 7-day oral treatment with CMA at 2.0 mg/kg/day in dogs with BPH last for about three months or longer without side effects.
authors.affiliation: Department of Radiology, Nippon Veterinary and Animal Science University, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Orima
authors.forename: M
authors.initials: M
authors.lastname: Shimizu
authors.forename: T
authors.initials: T
authors.lastname: Tsutsui
authors.forename: E
authors.initials: E
authors.lastname: Kawakami
authors.forename: A
authors.initials: A
authors.lastname: Ogasa
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002715:Chlormadinone Acetate / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D002715:Chlormadinone Acetate